Endpoints News 生物医药· Nicole DeFeudis·· 12 天前AI 评分50
Vir宣布慢性肝炎D药物组合在首个关键研究中取得成功
Vir says hepatitis D drug combination succeeds in first pivotal study
AI 导读
Vir Biotechnology 的慢性肝炎D治疗药物在首个关键研究中取得成功,与吉利德和Mirum Pharmaceuticals形成竞争。
正文
Vir Biotechnology’s chronic hepatitis D treatment has succeeded in the first of three late-stage studies, stoking competition with Gilead and Mirum Pharmaceuticals.
Vir said Sunday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news